164 related articles for article (PubMed ID: 2687716)
1. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Crossman AR; Peggs D; Boyce S; Luquin MR; Sambrook MA
Neuropharmacology; 1989 Nov; 28(11):1271-3. PubMed ID: 2687716
[TBL] [Abstract][Full Text] [Related]
2. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism.
Graham WC; Robertson RG; Sambrook MA; Crossman AR
Life Sci; 1990; 47(18):PL91-7. PubMed ID: 2250573
[TBL] [Abstract][Full Text] [Related]
3. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Page RD; Sambrook MA; Crossman AR
Neuroscience; 1993 Jul; 55(1):147-65. PubMed ID: 7688878
[TBL] [Abstract][Full Text] [Related]
4. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
[TBL] [Abstract][Full Text] [Related]
5. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Zuddas A; Oberto G; Vaglini F; Fascetti F; Fornai F; Corsini GU
J Neurochem; 1992 Aug; 59(2):733-9. PubMed ID: 1629743
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.
Fredriksson A; Gentsch C; Archer T
J Neural Transm Gen Sect; 1994; 97(3):197-209. PubMed ID: 7873129
[TBL] [Abstract][Full Text] [Related]
7. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
8. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
[TBL] [Abstract][Full Text] [Related]
9. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Arai N; Isaji M; Kojima M; Mizuta E; Kuno S
J Neural Transm (Vienna); 1996; 103(11):1307-16. PubMed ID: 9013417
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
[TBL] [Abstract][Full Text] [Related]
12. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
13. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
Rupniak NM; Boyce S; Steventon MJ; Iversen SD; Marsden CD
Ann Neurol; 1992 Jul; 32(1):103-5. PubMed ID: 1642462
[TBL] [Abstract][Full Text] [Related]
14. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
15. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
16. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
Degryse AD; Colpaert FC
Brain Res Bull; 1986 May; 16(5):561-71. PubMed ID: 3488798
[TBL] [Abstract][Full Text] [Related]
17. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
18. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
19. Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Blanchet PJ; Boucher R; Bédard PJ
Brain Res; 1994 Jul; 650(1):32-9. PubMed ID: 7953674
[TBL] [Abstract][Full Text] [Related]
20. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE
Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
